Amplitude Ventures

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics to meet the pressing medical needs of patients suffering from cancer and autoimmune diseases. The company leverages an advanced platform that employs continuously learning artificial intelligence and a comprehensive database of antigen-antibody interactions. This technology enables the creation of potent and selective antibody therapeutics, aimed at addressing significant gaps in treatment options for these challenging health conditions. By prioritizing tailored solutions, Ability Biologics seeks to enhance patient outcomes and contribute to advancements in the field of immunotherapy.

Reverb Therapeutics is focused on creating innovative treatments for cancer and other diseases. The company specializes in developing cytokine therapies that aim to promote targeted immune activation while minimizing toxicity. By utilizing bispecific antibodies, Reverb Therapeutics localizes endogenous cytokines to immune cells within the tumor microenvironment. This approach addresses the toxicity challenges associated with exogenously delivered cytokines, allowing for a more effective use of the body's existing cytokines to target cancer cells. Through this strategy, Reverb Therapeutics seeks to improve outcomes for cancer patients and advance the healthcare sector's capabilities in cancer treatment.

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

DrugBank is a developer of a comprehensive drug knowledge platform aimed at enhancing healthcare delivery and accelerating drug research. Its extensive database offers detailed information about drugs, their mechanisms of action, and interactions, which aids healthcare professionals in making informed decisions. The platform includes tools for drug search, interaction checking, allergy information, and drug labeling, facilitating precision medicine and clinical software applications. By integrating its knowledge base into various software solutions, DrugBank enables companies to leverage advanced insights and data science for drug discovery, helping to identify novel drug candidates and opportunities for drug repurposing. Additionally, DrugBank Online serves as a publicly available resource, offering limited datasets for academic and non-commercial researchers. With over 13,000 citations in academic publications, DrugBank is widely utilized by researchers and health professionals worldwide.

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

InVivo AI, founded in 2017 and based in Montreal, Canada, specializes in utilizing artificial intelligence to enhance pharmaceutical research and development, particularly in the area of preclinical toxicology. The company aims to streamline the drug discovery process by implementing advanced AI methods for molecular representation and de novo design, which allows for the creation of novel chemical compounds that can address complex biological challenges. Through its innovative platform, InVivo AI is positioned to significantly improve the efficiency and effectiveness of drug design, paving the way for breakthroughs in pharmaceutical science.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Xap Therapeutics is a biotechnology start-up based in Cambridge, established in 2017 by James Patterson, M.D., Ph.D. The company focuses on developing a synthetic biology-driven platform for cell therapeutics. This platform utilizes clustered regularly interspaced short palindromic repeats (CRISPR) technology to engineer induced pluripotent stem cells, which serve as a foundation for producing a specialized "chassis" cell. These chassis cells are further functionalized into various cell therapies through genetically engineered constructs. Xap Therapeutics aims to enhance the treatment of serious diseases, including autoimmunity and cancer, by leveraging its innovative approach to cell therapy.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics primarily for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various cancers such as biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials targeting advanced or metastatic HER2-expressing cancers. Zymeworks utilizes a combination of proprietary molecular modeling, simulation software, and high-performance computing to optimize therapeutic antibodies and other protein-based treatments. The company has established strategic partnerships with several leading pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Additionally, Zymeworks is advancing a preclinical pipeline that includes candidates for oncology and other therapeutic areas, reflecting its commitment to addressing unmet medical needs.

Shoebox develops validated iPad audiometers to help solve everyday problems faced by hearing health professionals and workplace safety managers. They offer solutions for occupational hearing testing. They offer validated online hearing screening, boothless diagnostic audiometers, and a comprehensive tele-audiology solution.

The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.

Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine. The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy, enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics.